BPH Treatment Market Analysis
Explore In-Depth BPH Treatment Market Analysis, Covering Detailed Segmentation and Geographical Insights for the Period of 2019 to 2030
Report Code: 12191
Explore In-Depth BPH Treatment Market Analysis, Covering Detailed Segmentation and Geographical Insights for the Period of 2019 to 2030
The larger benign prostatic hyperplasia treatment market share, of 85%, is held by drugs in 2024, and this bifurcation will also grow faster in the future. This is attributed to the burgeoning demand for alpha-blockers as these medications relax the muscle of the prostate and bladder neck, which enables urine to flow more easily. Among the different types of drugs, alpha-blockers have been widely utilized to treat the disease in recent years. Their increasing use and the abundance of medications under development present potential opportunities for the industry.
Additionally, due to the high demand for alpha-blockers, businesses such as Sun Pharmaceutical Industries Ltd. and Astellas Pharma Inc. continue to invest in this industry. The development of such medication, which may be used in both monotherapy and combination therapy, is driving their demand. They are a preferred medication for the treatment of benign prostatic hyperplasia since they are rather effective and inexpensive.
The types analyzed are mentioned below:
Home healthcare settings account for the larger share in the market in 2024, and they are expected to record the higher CAGR, of 6%, during the forecast period, due to the increasing number of patients prescribed drugs over surgical treatment. Moreover, a significant proportion of the population prefers drug-based treatment at their homes over treatment in hospitals. Further, patients are highly recommended to take medications for a couple of months after surgeries, which further bolsters the market expansion in this category.
The following end users are covered:
In 2024, North America accounts for the largest share, of 40%, in the BPH treatment market. The growing incidence of the problem is fueling the adoption of advanced treatments, such as laser therapy, prostatic stenting, and UroLift therapy, thereby driving the industry development in the region. Further, the favorable reimbursement policies and a rising number of trained surgeons will support the advance of the players in the region in the next few years.
The region has the presence of several device and drug manufacturers, who are strongly focused on conducting R&D activities and product innovations to enhance the quality of care. Additionally, there is high penetration of laser therapy owing to the availability of advanced healthcare infrastructure. Several clinics and urology centers are equipped with modern laser equipment to treat BPH, which, in turn, boosts the regional progress.
The APAC region is expected to witness the fastest growth during the forecast period, at a CAGR of 6.5%. The surging living standards, flourishing per capita income and spending capability, increasing urological disease burden, and rising investment in the healthcare sector inflate the progress.
Moreover, the burgeoning aging male population in the region, coupled with an escalation in the incidence of diabetes and obesity, is expected to drive the prevalence of BPH and other lower urinary tract conditions. China, Japan, and India together have a large elderly male population, which requires regular medical assistance, as it is highly susceptible to chronic diseases owing to its low immunity. Thus, patients with an irregular growth of the prostate are required to be treated, to prevent urethra blockage and reduce the associated cancer risk.
For instance, the prevalent cases and incident cases of BPH in China were approximately 20.34 million and 2.84 million, respectively, and the standardized incidence rate and standardized prevalence rate were 280.64/100,000 and 2,220.85/100,000, respectively, in 2019. Similarly, in India, it is an ordinary elderly problem, with an incidence of 93.3%, which fosters the demand for drugs as well as surgical treatments.
We studied the following regions and countries:
Want a report tailored exactly to your business need?
Request CustomizationWorking with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
IndiaOur insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages